Biotechnology
Filter News
Found 46,688 articles
-
Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
7/31/2019
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
-
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019
7/31/2019
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced an oral presentation will be given at the 28th EADV Congress.
-
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
7/31/2019
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 5:00 p.m. ET.
-
Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study
7/31/2019
Axcella Health, (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions using novel compositions of endogenous metabolic modulators to address dysregulated metabolism and support health, announced the publication of data describing the safety, tolerability and impact of investigational product AXA2678 on short-term muscle disuse atrophy in young healthy men.
-
BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.
7/31/2019
BioInvent International AB announces that Pfizer Inc. has selected the first target under the companies' cancer immunotherapy research collaboration and license agreement, into which the companies entered in December 2016 to develop antibodies targeting tumor-associated myeloid cells.
-
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
7/31/2019
REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, announced it entered into a license agreement with Pfizer Inc.
-
GHO Capital Announces the Sale of Caprion Biosciences
7/31/2019
Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, announces the sale of Caprion Biosciences to Arsenal Capital Partners, a leading specialized private equity firm that invests in middle-market healthcare and specialty industrials companies.
-
Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
7/31/2019
Rocket Pharmaceuticals, Inc., a leading U.S.-based multi-platform clinical-stage gene therapy company, announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, August 7, 2019, at 1:30p.m.
-
Biological E and GVK BIO Announce Strategic R&D Partnership
7/31/2019
GVK BIO, a leading global Contract Research and Development Organisation, and BE Pharmaceuticals Inc, a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.
-
Caprion Biosciences and HistoGeneX Unite Businesses to Create Global Leader in Immune Monitoring and Biomarker Development
7/31/2019
Partnership Facilitated by Major Investment from Arsenal Capital Partners
-
Evogene Reports Second Quarter of 2019 Financial Results
7/31/2019
Evogene Ltd., a leading biotechnology company developing novel products for life science markets, announced its financial results for the second quarter ending June 30, 2019.
-
Bio-Up Mimetic Technologies Inc. Launches Functional Beverage Brand, Bio-Up®
7/31/2019
Proprietary liposomal technology significantly increases nutrient absorption by 370 percent
-
Vertex Reports Second-Quarter 2019 Financial Results
7/31/2019
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2019 and increased its full-year 2019 total product revenue guidance.
-
Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)
7/31/2019
Alligator Bioscience, announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc.
-
Portage Confirms Delay in Annual Filings; Expects Issuance of Cease Trade Order
7/31/2019
Portage Biotech Inc. announced that, further to its news release of July 26, 2019, it will be delayed in filing its audited annual financial statements for the year ended March 31, 2019, the related management's discussion and analysis and certificates of its CEO and CFO with Canadian securities regulators until after deadline.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 31, 2019
7/31/2019
PTC Therapeutics, Inc. announced that on July 26, 2019 it approved non-statutory stock options to purchase an aggregate of 208,100 shares of its common stock to 72 new employees.
-
ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report
7/31/2019
Benitec Biopharma, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, announced its Appendix 4C for the quarter ending 31 July 2019.
-
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
7/31/2019
Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately.
-
Caris Life Sciences to Present at Canaccord Genuity Annual Growth Conference
7/31/2019
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced that Brian J. Brille, Vice Chairman of the Company, will present at the Canaccord Genuity's 38th Annual Growth Conference on Wednesday, August 7, 2019, at 10 a.m. Eastern time.
-
Oregon Bioscience Association Appoints Eight New Board Members
7/31/2019
Oregon Bioscience Association announced the appointments of Peter Barr-Gillespie, Ph.D., Heather Ellis, Ritchard Englehardt, M.A., Tina Guldberg, Lisa Hale, Sean McClain, Todd Predmore, and Sandra Shotwell, Ph.D., to its board.